By Josh White
Date: Tuesday 15 Feb 2022
(Sharecast News) - Clinical diagnostics developer Verici Dx announced on Tuesday that its two lead in-vitro diagnostic assays, 'Clarava' and 'Tuteva', had completed analytical validation under the CLIA requirements, meeting criteria for robust assay performance.
By Josh White
Date: Wednesday 05 Jan 2022
(Sharecast News) - Organ transplant clinical diagnosis developer Verici Dx announced a collaboration with Nasdaq-listed Illumina on Wednesday, to expedite the operational launch of data analysis processing and the predictive artificial intelligence component of its products using early access to Illumina's new software platform ICA.
By Josh White
Date: Tuesday 04 Jan 2022
(Sharecast News) - Organ transplant diagnostics company Verici Dx has been granted 'CPT' proprietary laboratory analyses (PLA) codes for both its 'Clarava' and 'Tuteva' tests by the American Medical Association (AMA), it announced on Tuesday.
Currency | UK Pounds |
Share Price | 11.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 27.50 |
52 Week Low | 4.75 |
Volume | 17,076 |
Shares Issued | 170.32m |
Market Cap | £18.74m |
RiskGrade | 429 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:29 | 3,576 @ 10.68p |
09:12 | 13,500 @ 11.37p |
You are here: research